Imax Corp’s recently made public that its Officer Richard Gelfond acquired Company’s shares for reported $2.71 million on May 19 ’25. In the deal valued at $27.14 per share,100,000 shares were bought.
Then, GELFOND RICHARD L sold 100,000 shares, generating $2,711,440 in total proceeds. Upon selling the shares at $27.11, the Chief Executive Officer now owns 604,599 shares.
Before that, Demirian Eric A sold 23,000 shares. Imax Corp shares valued at $616,630 were divested by the Director at a price of $26.81 per share. As a result of the transaction, Demirian Eric A now holds 35,007 shares, worth roughly $0.97 million.
A number of analysts have revised their coverage, including Seaport Research Partners’s analysts, who began to cover the stock in late July with a ‘”a Buy”‘ rating. Barrington Research also remained covering IMAX and reiterated its “an Outperform” recommendation on April 21, 2023. B. Riley Securities maintained its rating on December 05, 2022. It rated IMAX as “a Buy”.
Price Performance Review of IMAX
On Friday, Imax Corp [NYSE:IMAX] saw its stock jump 0.66% to $27.65. Over the last five days, the stock has lost -0.72%. Imax Corp shares have risen nearly 8.01% since the year began. Nevertheless, the stocks have risen 77.59% over the past one year. While a 52-week high of $28.42 was reached on 06/02/25, a 52-week low of $14.94 was recorded on 04/11/25. SMA at 50 days reached $25.35, while 200 days put it at $23.96.
Levels Of Support And Resistance For IMAX Stock
The 24-hour chart illustrates a support level at 27.49, which if violated will result in even more drops to 27.32. On the upside, there is a resistance level at 27.87. A further resistance level may holdings at 28.08. The Relative Strength Index (RSI) on the 14-day chart is 62.60, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.10, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 36.49%. Stochastics %K at 61.64% indicates the stock is a holding.
The most recent change occurred on October 12, 2022 when B. Riley Securities resumed its ‘”a Buy”‘ rating for the stock and retained the price target to $20.
